Novel oligonucleotides data presented at Options Conference
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Noxopharm Ltd. presented promising data on its novel oligonucleotides at the Options XIII Conference, aimed at improving next-generation mRNA vaccines. The research indicates that Noxopharm's technology could reduce inflammation associated with self-amplifying mRNA vaccines, enhancing their tolerability. CEO Dr. Olivier Laczka highlighted the versatility of their Sofra platform, which is attracting interest for its potential applications in vaccine and drug development.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Noxopharm
- Appendix 4E - Preliminary Financial Report
- New preclinical data supports immuno-oncology approach
- Quarterly Activities/Appendix 4C Cash Flow Report
- SOF-SKN manufacturing begins to ensure clinical trial readi
- New data confirms cancer-fighting potential
Later from Noxopharm
All Noxopharm news releasesFollow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm